RESUMO
Rifabutin (ansamycin LM 427), a semisynthetic spiropiperidyl derivative of rifamycin S, shows good in vitro activity against most mycobacterial species, including Mycobacterium avium complex. In animal models, the drug is more active against both Mycobacterium tuberculosis and Mycobacterium leprae than in rifampin, and studies indicate that rifabutin is active against some rifampin-resistant strains of both species. The drug has a long half-life (16 hr) in humans and a marked tissue tropism, with tissue levels five- to 10-fold higher than that in the serum. In animals rifabutin is no more toxic than rifampin. A large experience from the compassionate use of rifabutin for life-threatening mycobacterial infections in humans, most commonly disseminated M. avium complex disease in patients with AIDS, has also indicated relative drug safety. Although some data suggest that rifabutin is effective, firm conclusions about drug efficacy await results from controlled clinical trials.
Assuntos
Infecções por Mycobacterium/tratamento farmacológico , Rifamicinas/uso terapêutico , Tuberculose Pulmonar/tratamento farmacológico , Síndrome da Imunodeficiência Adquirida/complicações , Animais , Resistência Microbiana a Medicamentos , Humanos , Mycobacterium/efeitos dos fármacos , Mycobacterium avium/efeitos dos fármacos , Rifabutina , Rifamicinas/efeitos adversos , Rifamicinas/farmacologiaRESUMO
Os autores relatam os resultados obtidos com a rifampicina no tratamento de 10 pacientes de hanseníase virchoviana, clinicamente resistentes à sulfonoterapia. São apresentadas as observações clínicas, os exames baciloscópicos, histopatológicos, de sangue, urina e as provas de função hepática. Os resultados siginificativos levam os autores a confirmar a ação do medicamento e sua indicação como de escolha nos casos de hanseníase sulfono-resistente.